Study of Plasminogen activator inhibitor-1 (PAI-1) in hospitalized COVID-19 patients

Boshta, Aya Mohamed; Fouda, Mohamed Hossny; Hantera, Mohamed Sayed; El-Zamrany, Enass Arafa

doi:10.21608/ejhm.2023.286415

Study of Plasminogen activator inhibitor-1 (PAI-1) in hospitalized COVID-19 patients

Document Type : Original Article

Authors

10.21608/ejhm.2023.286415

Abstract

Background: There is an evidence that COVID-19 individuals have impaired fibrinolysis, which may increase their thrombotic risk further. Hepatocytes and endothelial cells are responsible for the synthesis of plasminogen activator inhibitor-1 (PAI-1). It is the primary inhibitor of tissue-type plasminogen activator (t-PA) and has a crucial role in fibrinolysis control. The purpose of our research was to measure the plasma levels of PAI-1 in Patients with COVID-19 who were hospitalized.
Methods:In the current research, 40 Patients with COVID-19 and 40 healthy participants served as controls. Enzyme-linked immune-sorbent assay (ELISA) was used to measure plasma PAI-1 levels.
Results: There was a considerable elevation in WBCs count and segmented WBCs in cases compared to control with significant decrease in lymphocytes in cases compared to control group. PAI-1, CRP, LDH, Ferritin and D-Dimer were remarkably raised in patients compared to control group.There was positive significant correlation between PAI-1 levels and urea, creatinine, AST, LDH, ferritin, D-Dimer and CRP. PAI-1 showed 93% sensitivity and 87% specificity at cut off 5.5 ng/ml in discriminating patients from control group < strong>.
Conclusions: Plasma concentrations of PAI-1, a measure of fibrinolytic homeostasis, were higher in ICU patients with COVID-19. This research also showed that PAI-1 may be added to the list of biomarkers used to define Patients with COVID-19.

Keywords